J. Kevin Leach, K. Spencer, M. Mascelli
Mar 1, 2015
Citations
0
Influential Citations
16
Citations
Journal
Clinical Pharmacology in Drug Development
Abstract
Icatibant is a bradykinin‐2 receptor antagonist approved to treat acute hereditary angioedema attacks in adults. To‐date, no thorough investigation of the clinical pharmacokinetic (PK) parameters of icatibant and its primary metabolites has been reported. Here we present the PK results of two phase I clinical studies of icatibant in healthy human volunteers.